Australian Pharmaceutical Industries Ltd
ASX:API
Balance Sheet
Balance Sheet Decomposition
Australian Pharmaceutical Industries Ltd
Australian Pharmaceutical Industries Ltd
Balance Sheet
Australian Pharmaceutical Industries Ltd
| Aug-2012 | Aug-2013 | Aug-2014 | Aug-2015 | Aug-2016 | Aug-2017 | Aug-2018 | Aug-2019 | Aug-2020 | Aug-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
20
|
23
|
24
|
28
|
25
|
40
|
36
|
30
|
61
|
39
|
|
| Cash |
20
|
23
|
24
|
28
|
25
|
40
|
36
|
30
|
61
|
39
|
|
| Total Receivables |
586
|
561
|
566
|
595
|
690
|
682
|
655
|
658
|
538
|
589
|
|
| Accounts Receivables |
543
|
529
|
534
|
568
|
660
|
659
|
655
|
658
|
538
|
589
|
|
| Other Receivables |
44
|
32
|
32
|
27
|
29
|
23
|
0
|
0
|
0
|
0
|
|
| Inventory |
314
|
336
|
343
|
364
|
414
|
399
|
395
|
413
|
368
|
353
|
|
| Other Current Assets |
0
|
0
|
0
|
7
|
0
|
0
|
0
|
0
|
7
|
9
|
|
| Total Current Assets |
920
|
919
|
932
|
994
|
1 129
|
1 121
|
1 086
|
1 101
|
973
|
990
|
|
| PP&E Net |
121
|
122
|
117
|
102
|
100
|
95
|
101
|
107
|
235
|
231
|
|
| PP&E Gross |
121
|
122
|
117
|
102
|
100
|
95
|
101
|
107
|
235
|
231
|
|
| Accumulated Depreciation |
118
|
129
|
139
|
125
|
128
|
135
|
151
|
164
|
173
|
190
|
|
| Intangible Assets |
100
|
106
|
122
|
148
|
143
|
144
|
178
|
174
|
136
|
126
|
|
| Note Receivable |
76
|
61
|
31
|
30
|
10
|
20
|
27
|
57
|
22
|
10
|
|
| Long-Term Investments |
28
|
28
|
7
|
0
|
0
|
0
|
0
|
88
|
1
|
2
|
|
| Other Long-Term Assets |
37
|
40
|
35
|
23
|
21
|
21
|
24
|
32
|
44
|
42
|
|
| Other Assets |
92
|
101
|
45
|
46
|
47
|
50
|
105
|
106
|
128
|
129
|
|
| Total Assets |
1 373
N/A
|
1 376
+0%
|
1 289
-6%
|
1 343
+4%
|
1 450
+8%
|
1 451
+0%
|
1 521
+5%
|
1 665
+9%
|
1 540
-8%
|
1 530
-1%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
530
|
562
|
567
|
609
|
749
|
752
|
0
|
0
|
0
|
0
|
|
| Accrued Liabilities |
48
|
61
|
67
|
80
|
73
|
72
|
22
|
22
|
23
|
27
|
|
| Short-Term Debt |
4
|
4
|
3
|
2
|
1
|
2
|
2
|
5
|
8
|
21
|
|
| Current Portion of Long-Term Debt |
40
|
22
|
18
|
57
|
2
|
1
|
1
|
55
|
40
|
46
|
|
| Other Current Liabilities |
42
|
13
|
32
|
30
|
21
|
25
|
15
|
15
|
19
|
11
|
|
| Total Current Liabilities |
663
|
661
|
687
|
778
|
846
|
851
|
818
|
887
|
833
|
825
|
|
| Long-Term Debt |
0
|
0
|
14
|
41
|
48
|
30
|
89
|
170
|
212
|
247
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
4
|
2
|
|
| Other Liabilities |
142
|
131
|
108
|
19
|
18
|
16
|
103
|
86
|
40
|
17
|
|
| Total Liabilities |
805
N/A
|
792
-2%
|
808
+2%
|
837
+4%
|
913
+9%
|
897
-2%
|
1 013
+13%
|
1 146
+13%
|
1 089
-5%
|
1 091
+0%
|
|
| Equity | |||||||||||
| Common Stock |
567
|
567
|
567
|
566
|
566
|
566
|
566
|
566
|
566
|
566
|
|
| Retained Earnings |
11
|
21
|
85
|
60
|
31
|
12
|
58
|
50
|
116
|
130
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Equity |
9
|
3
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
3
|
|
| Total Equity |
568
N/A
|
584
+3%
|
481
-18%
|
505
+5%
|
537
+6%
|
554
+3%
|
509
-8%
|
519
+2%
|
451
-13%
|
439
-3%
|
|
| Total Liabilities & Equity |
1 373
N/A
|
1 376
+0%
|
1 289
-6%
|
1 343
+4%
|
1 450
+8%
|
1 451
+0%
|
1 521
+5%
|
1 665
+9%
|
1 540
-8%
|
1 530
-1%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
488
|
488
|
488
|
488
|
489
|
490
|
492
|
493
|
493
|
493
|
|